MedTrace Logo

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

NCT01769547 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-09-17

No results posted yet for this study

Summary

This is a single-arm, open label, two stage, phase II study of dovitinib in patients with advanced Malignant Pleural Mesothelioma (MPM). The primary purpose of this study is to evaluate the potential efficacy of dovitinib in the second- or third-line treatment of MPM using progression free survival (PFS).

Conditions

  • Advanced Malignant Pleural Mesothelioma
  • MPM

Interventions

DRUG

Dovitinib

Treatment continued until Disease Progression, Toxicity, or patient withdrawal.

Sponsors & Collaborators

Principal Investigators

  • Scott Laurie, MD · Ottawa General Hospital Cancer Centre

  • Mark Levine, MD · Ontario Clinical Oncology Group (OCOG)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01769547 on ClinicalTrials.gov